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Abstract 
Aims: Due to their significant biological activity, thiosemicarbazones (TSCs) are promising 
candidates for anticancer therapy. In part, the efficacy of TSCs is linked to their ability to 
chelate essential metal ions such as copper and iron. Triapine, the best-studied anticancer 
TSC, has been tested clinically with promising results in hematological diseases. During the 
last years, a novel subclass of TSCs with improved anticancer activity was found to induce 
paraptosis, a recently characterized form of cell death. The aim of this study was to 
identify structural and chemical properties associated with anticancer activity and 
paraptosis induction of TSCs. 
Results: When testing a panel of structurally related TSCs, compounds with nanomolar 
anticancer activity and paraptosis-inducing properties showed higher copper(II) complex 
solution stability and a slower reduction rate, which resulted in reduced redox activity. In 
contrast, TSCs with lower anticancer activity induced higher levels of superoxide that 
rapidly stimulated superoxide dismutase expression in treated cells, effectively protecting 
the cells from drug-induced redox stress. 
Innovation: Consequently, we hypothesize that in case of close Triapine derivatives, 
intracellular reduction leads to rapid dissociation of intracellularly formed copper 
complexes. In contrast, TSCs characterized by highly stable, slowly reducible copper(II) 
complexes are able to reach new intracellular targets such as the ER-resident protein 
disulfide isomerase. 
Conclusions: The additional modes of actions observed with highly active TSC derivatives 
are based on intracellular formation of stable copper complexes, offering a new approach 
to combat (drug-resistant) cancer cells.  
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Introduction  
Thiosemicarbazones (TSCs) possess significant biological activity, which resulted in their 
development as pharmaceuticals against several diseases, including cancer (24). In part, 
the efficacy of TSCs is linked to their ability to chelate essential metal ions such as copper 
and iron. Cancer cells, in particular, require higher amounts of these metal ions due to 
their increased rate of replication (3,60). As a result, the ability of α-N-heterocyclic TSCs to 
form stable metal complexes is an important property for their development as anticancer 
agents (26).  
Initially, the mechanism of action of α-N-heterocyclic TSCs was thought to primarily rely on 
the depletion of iron and the consequential inhibition of the iron-containing enzyme 
ribonucleotide reductase (57). However, the role of other metals (especially copper), 
metalloenzymes and metal-interacting proteins is gaining more attention (16,22). For 
example, the ability of copper(II)-TSC complexes to undergo redox cycling in the presence 
of reducing agents, with production of reactive oxygen species (ROS) (a process also called 
“activation by reduction” (22)), and the disruption of the cellular thiol redox homeostasis is 
increasingly discussed as relevant contributions to TSC activity (11,23,27,44). Furthermore, 
the interaction with copper ions has been recently suggested to be involved in collateral 
sensitivity of P-glycoprotein (P-gp, ABCB1)-overexpressing multidrug-resistant cancer cells 
to the nanomolar-active TSC di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone 
(Dp44mT) (21). Interestingly, recently performed studies confirmed the enhanced 
sensitivity of certain P-gp-overexpressing cells (e.g. MES-SA/Dx5) to several metal 
chelators (including Dp44mT), but also suggested that the collateral sensitivity of these 
MDR cells may rely on other (more complex) mechanisms independent of P-gp transport 
function (9,40). 
With regard to the clinical situation, the best studied anticancer TSC, Triapine, has been 
already tested in several phase I and II trials with promising results especially against 
hematological diseases (12,25,54,56,59). Currently, this drug is being investigated as 
chemo- and radiosensitizer in an ongoing clinical phase III study assessing Triapine in 
combination with cisplatin and radiation therapy (NCT02466971) (30). In addition, two 
other α-N-heterocyclic TSCs di-2-pyridylketone 4-cyclohexyl-4-methyl-3-
thiosemicarbazone (DpC) and 4-(pyridine-2-yl)-N-{[(8E)-5,6,7,8-tetrahydroquinolin-8-
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ylidene]amino})piperazine-1-carbothioamide (Coti-2) recently entered clinical phase I trials 
(www.clinicaltrials.gov). Noteworthy, these two compounds as well as Dp44mT (the 
predecessor of DpC) and our dimethylated Triapine derivative Me2NNMe2 represent a 
subclass of TSCs characterized by a ~500-fold higher anticancer activity compared to 
Triapine in cell culture (20,37). Recent studies suggested that this efficiency could be based 
on an additional mode-of-action, associated with the formation of intracellular copper 
complexes (16,19,34). In particular, our group discovered that these compounds are able 
to induce paraptosis, a novel form of programmed cell death (13). Paraptosis is a caspase-
independent cell death discernable by the appearance of cytoplasmic vesicles originating 
from the endoplasmic reticulum (ER) (33,50). TSC-induced paraptosis appears to be 
associated with the (copper-dependent) inhibition of the ER-resident protein disulfide 
isomerase (PDI) (13). In light of these recent data, the aim of this study was to elucidate 
the role of copper complex formation of various TSCs in anticancer activity, paraptosis 
induction and collateral sensitivity. For this purpose, we investigated solution stability and 
redox properties of a selected panel of structurally related α-N-heterocyclic TSCs and their 
respective copper(II) complexes. The measured physico-chemical properties were then 
correlated with biological parameters (anticancer activity, resistance ratio of multidrug-
resistant (MDR) cancer cells, paraptosis induction and PDI inhibition). Thus, we show that 
highly active TSCs (with IC50 values in the nanomolar range) form copper(II) complexes 
characterized by high stability and slow reduction kinetics. Our data suggest that these 
stability and redox properties protect the copper(II) complexes of this TSC subclass from 
premature reduction-induced ligand liberation allowing the interaction of the copper(II) 
complexes with intracellular targets such as the ER-resident PDI. In contrast, the copper 
complexes of TSCs such as Triapine are sensitive to rapid reduction and thus ligand 
liberation inside the cancer cells, which are efficiently protected from the generated 
superoxide by the upregulated enzyme superoxide dismutase (SOD) in cell culture as well 
as in a tumor model in vivo. 
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Results 
Anticancer activity and paraptosis-inducing potential of the TSC panel 
As a first step, the in vitro anticancer activity of the selected α-N-pyridyl TSCs (see Table 1 
for their chemical formulae) and their preformed (i.e. in situ generated) copper(II) 
complexes (in a 1:1 metal-to-ligand ratio) was measured in human colon adenocarcinoma 
SW480 and uterine sarcoma MES-SA cells as well as the multidrug-resistant subline MES-
SA/Dx5. SW480 cells were investigated by conventional MTT assay, while the fluorescently 
labelled MES-SA and MES-SA/Dx5 cells were tested in co-culture using an automated 
system (Figure 1A and B, Table 1 and 2 as well as Suppl. Table 1 - 4) (55). In accordance to 
previous reports (27-29,47,52), following 72 or 144 h incubation, the three terminally 
dimethylated compounds pyridine-2-carbaldehyde thiosemicarbazone (PTSC), Me2NNMe2, 
Dp44mT and the disubstituted derivative DpC showed distinctly higher anticancer activities 
than the other compounds (2-formylpyridine thiosemicarbazone (FTSC), Triapine, 
H2NNHMe, H2NNMe2, MeHNNMe2, Me2NNH2, Me2NNHMe). This was especially 
pronounced in the MES-SA/Dx5 cell model, reflecting the collateral sensitivity of the P-gp-
overexpressing cells to this subtype of TSCs (Table 1 and 2, Figure 1B).  
In order to gain more insight into the time dependency of these effects, the activity of the 
compounds was also assessed after 3 and 24 h. None of the metal-free ligands exhibited 
relevant anticancer activity after 3 h resulting in IC50 values above the highest tested 
concentration of 25 µM. With the exception of PTSC, Dp44mT and DpC, the compounds 
did not decrease viability following a 24 h-long incubation with the tested cancer cells. 
Interestingly, in contrast to the later time points (Figure 1B), collateral sensitivity of MES-
SA/Dx5 cells was not observed at 24 h (Suppl. Table 2 and 3), indicating that the collateral 
sensitivity might be based on enhanced cell cycle arrest rather than enhanced apoptosis. 
The anticancer activity of copper(II) complexes was slightly different (Table 1 and 2 as well 
as Suppl. Table 1 - 4). Several complexes were already active after a relatively short 
incubation time (24 h) in SW480 cells (Suppl. Table 1 - 3), showing the same activity 
pattern as observed in the 72 h experiment (Table 1). However, after 72 h IC50 values of all 
tested copper complexes were in a similar range as the respective metal-free ligands 
(Figure 1A, Table 1), with the exception of Me2NNHMe, which was significantly more active 
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as a copper(II) complex. Thus, the long-germ anticancer activity of the copper complexes 
of the nanomolar-active TSCs was similar to that of the respective metal-free ligand.  
In order to investigate the paraptosis-inducing potential of the compounds, perinuclear 
vesicle formation was investigated by microscopy after drug treatment (Figure 1C). In 
agreement with previous results (13), Me2NNMe2, Dp44mT and DpC induced high levels of 
vacuolization in SW480 cells already at 0.1 µM drug concentrations (Figure 1C and D). In 
addition, also incubation with the terminally dimethylated PTSC, H2NNMe2 and 
MeHNNMe2 likewise induced paraptosis (however, vacuolization at 0.1 µM was observed 
only in case of PTSC, while for the other two derivatives, the effect was visible only at 1 
µM, reflecting their higher IC50 values). Similar results were obtained in MES-SA cells 
(Suppl. Figure 2).  
Proton dissociation processes and pKa values of the investigated TSCs 
As there is a distinct structure-activity relationship in our TSCs panel, subsequently, we 
characterized whether these effects are reflected by differences in their chemical 
properties. While for Triapine and some derivatives several reports on proton dissociation 
processes are available (5-7), for most of the compounds in this study this parameter has 
not been characterized so far (especially not in pure aqueous solution). First, pKa values 
were determined by UV-visible (UV-vis) spectrophotometric titrations in pure water at 
compound concentrations of 10-50 µM. In case of DpC, addition of some dimethyl 
sulfoxide (DMSO) was necessary and the pKa values of DpC in pure water were estimated 
by extrapolation (Table 3; Suppl. Figure 3A). For all compounds, the measured UV-vis 
spectra revealed characteristic changes upon increasing pH, as it is depicted exemplarily 
for Me2NNMe2 in Figure 2A. The pH-dependence of the absorbance values always showed 
two well-separated deprotonation steps: one at pH 2.5‒6.0 and one at 8.0-11.5. Therefore, 
two pKa values could be determined (Table 3). The λmax and  values of the ligand species in 
the different protonation states are collected in Suppl. Table 5. The calculated individual 
spectra (e.g. for Me2NNMe2 in Suppl. Figure 3B) represent significant differences between 
the molar absorptivities of the various ligand species (Suppl. Table 5). Notably, the pKa of 
the second pyridyl moiety in Dp44mT and DpC could not be determined under the applied 
conditions due to its fairly acidic character. Analysis of the pKa values revealed that N-
terminal dimethylation results in slightly higher pKa (H2L
+) and lower pKa (HL) (Triapine vs. 
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H2NNMe2 or FTSC vs. PTSC etc.), whereas dimethylation of the pyridine amine increases 
slightly both pKa values (Triapine vs. Me2NNH2). At the same time monomethylations have 
only a minor influence. The dipyridyl derivatives Dp44mT, DpC as well as FTSC and PTSC 
possess decreased pKa H2L
+ by almost one order of magnitude, but no clear trend was 
evident for pKa HL. In general, not only the electron-donating/withdrawing properties of 
the substituents should be considered to explain differences in pKa values, but also the 
ability of the derivatives to be stabilized by mesomeric/resonance effects (e.g. the 
thione/thiol equilibrium). As apparent from the determined pKa values all TSCs 
investigated in this study are charge neutral (in HL form) at physiological pH. 
High copper(II) complex solution stability is an important parameter for anticancer 
activity 
Having characterized the (de)protonation behavior of our TSCs, we evaluated the stability 
of the respective copper complexes in aqueous solution. Based on our previous findings 
(5,6), we assumed that some of the studied α-N-pyridyl TSCs (Triapine, FTSC, PTSC, 
H2NNMe2) form very stable [CuL]
+ complexes in a wide pH range. At lower pH, the balance 
shifts to [CuLH]2+ complexes, containing the protonated ligand. In contrast, a mixed 
hydroxido complex [CuL(OH)] is prevalent in the basic pH range, while at ligand excess 
further species (e.g. [CuL2], [Cu2L3]
+) can be found (6).  
Equimolar aqueous solutions of the metal ion and the respective ligands (10 or 25 µM 
concentration) were titrated and the deprotonation processes of the complexes were 
followed spectrophotometrically (Figure 2B for Cu-Me2NNH2). Deconvolution of the 
spectra resulted in the pKa values of the copper(II) complexes and their individual 
absorbance spectra (Suppl. Table 6, Suppl. Figure 3C). All pKa values were in the range of 
2.1-2.6 (for [CuLH]2+) and 8.1-8.8 (for [CuL]+) and thus well comparable to reported data of 
FTSC (with 1% DMSO) (1). In general, the pKa value of [CuLH]
2+ was by 7.2-8.6 orders of 
magnitude lower compared to that of the metal-free HL form, revealing that displacement 
of the dissociable proton in the complex is mediated by the metal ion coordination. As the 
formation of the complex [CuL]+ is predominant in a wide pH range (4‒6.5) (Figure 2C for 
Cu-Triapine) and assumed to be quantitative due to the high solution stability, apparent 
(conditional) formation constants (β′) for this type of complexes were subsequently 
determined by competition experiments with EDTA (24) (Figure 2D for 1:1 Cu-Me2NNHMe 
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and Suppl. Figure 3D). Since the displacement was found to be relatively slow, 1–2 h 
equilibration time was applied for this reaction (the reverse experiment using Cu-EDTA + 
FTSC resulted in the same endpoint; see Suppl. Figure 4). Increasing amounts of EDTA 
resulted in decreasing absorbance at the wavelength characteristic for the S→Cu charge 
transfer band (e.g. 422 nm in case of Me2NNHMe in Figure 2D). Taken into account the 
conditional stability constants determined (Suppl. Table 6) as well as the proton 
dissociation constants of the ligands (Table 3), the overall stability constants (β) of the 
complexes [CuL]+ were calculated (Table 3). Furthermore, also the β values of the other 
two types of complexes [CuLH]2+ and [CuL(OH)] were computed (Table 3) using the pKa of 
[CuLH]2+ and [CuL]+ (Suppl. Table 6). Based on these data, it can be concluded that at 
physiological pH, [CuL]+ is the most predominant species, accompanied by a smaller 
fraction (3.9-16.3%) of [CuL(OH)] (Table 3, Figure 2C). 
Since a direct comparison of the logβ [CuL]+ constants is not adequate due to the different 
basicity of the ligands, pCu (−log [Cu(II)]) values were calculated in order to compare the 
copper(II)-binding ability of the studied TSCs at pH 7.4 (a higher pCu value indicates a 
stronger metal ion-binding ability of the ligand) (Table 3). The calculated pCu values 
revealed that dimethylation at both the terminal and the pyridine amino group increased 
complex stability. On the contrary, the effect of monomethylation on the copper(II)-
binding ability was minor at both positions. Undoubtedly, the four compounds with 
activity in the nanomolar range form copper(II) complexes with the highest stability, 
followed by the two trimethylated compounds MeHNNMe2 and Me2NNHMe and all other 
derivatives (Table 3).  
To evaluate the effect of copper complex stability on the biological activity, the pCu and 72 
h pIC50 values of either the ligands or their in situ generated copper complexes were 
correlated. These analyses revealed that the ligands with high pIC50 values possess a higher 
copper(II)-binding ability (indicated by higher pCu values) and the correlation is even more 
pronounced for the pIC50 values of the copper(II) complexes (Figure 2E and Suppl. Figure 
4). Accordingly, the higher copper complex stability was also associated with higher 
activity in the multidrug-resistant cells after long-term incubations (Figure 2F) and 
paraptosis induction (Figure 2G), indicating an important role of the copper(II) complex in 
these TSC-induced effects. 
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Reduced reduction rate of copper(II) complex has a strong impact on TSC activity 
In addition to the stability of the formed copper(II) complexes, also their redox properties 
may have an impact on their biological activities. In order to investigate, whether there are 
differences in the reduction rates of our TSC panel, the redox reactions of the in-situ 
generated copper(II) complexes with two physiological reducing agents, namely ascorbic 
acid (AA) and L-glutathione (GSH), were studied. Reduction of the copper(II) complexes 
was followed spectrophotometrically in aqueous solution at pH 7.4 under anaerobic 
conditions.  
In good agreement with the literature (11), no time-dependent spectral changes were 
observed in the case of AA which suggests that these metal complexes cannot be reduced 
by AA under the applied conditions (see Suppl. Figure 5). This could be explained by the 
relatively weak reducing power of ascorbate (formal potential at pH 7.4: +0.05 V for 
dehydro-L-ascorbate/AA) (15). In contrast, the stronger reducing agent GSH (formal 
potential at pH 7.4: −0.26 V for GSSG/GSH (45) reduced all studied copper(II) TSC 
complexes, although with different rates (Figure 3A and B).  
The first recorded spectrum after mixing the reactants showed a small shift of the λmax 
value (e.g. 448 → 452 nm, as shown for Cu-MeHNNMe2 in Figure 3A) most probably due to 
the formation of a mixed ligand complex with GSH, as it is reported for various TSC 
complexes (22,44). This shift was followed by a significant decrease of the absorbance at 
this λmax, while the absorbance value at the λmax of the free ligand (~382 nm) increased, 
probably as a result of the decomposition of the generated unstable copper(I) complex. 
Noteworthy, oxygenizing (bubbling O2 into) the solution regenerated the original copper(II) 
complexes, confirming the reversibility of the redox process (data not shown). The other 
studied TSCs behaved similarly. However, significant differences were observed regarding 
the reduction rates of the respective complexes (Figure 3B). In order to obtain comparable 
data, the recorded absorbance/time curves were further analyzed at the λmax of the 
complexes. The calculated kobs, half-lives (t1/2) and percentage of non-reduced complex 
after 1 h in the presence of 50 equiv. (1.25 mM) of GSH are collected in Table 4. For 
selected complexes (Triapine, PTSC), kinetic runs were additionally performed at other 
equivalents of GSH, and kobs were found to be very sensitive to the concentration of the 
reducing agent, namely slower reaction rates with decreasing excess of GSH were 
D
ow
nl
oa
de
d 
by
 N
or
th
w
es
te
rn
 U
ni
ve
rs
ity
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
5/
03
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 11 of 67 
 
 
 
11 
A
n
ti
o
xi
d
an
ts
 a
n
d
 R
e
d
o
x 
Si
gn
al
in
g
 
H
ig
h
 c
o
p
p
er
 c
o
m
p
le
x 
st
ab
ili
ty
 a
n
d
 s
lo
w
 r
e
d
u
ct
io
n
 k
in
et
ic
s 
as
 k
e
y 
p
ar
am
e
te
rs
 f
o
r 
im
p
ro
ve
d
 a
ct
iv
it
y,
 p
ar
ap
to
si
s 
in
d
u
ct
io
n
 a
n
d
 i
m
p
ac
t 
o
n
 d
ru
g-
re
si
st
an
t 
ce
lls
 o
f 
an
ti
ca
n
ce
r 
th
io
se
m
ic
ar
b
az
o
n
es
 (
D
O
I:
 
1
0
.1
0
8
9
/a
rs
.2
0
1
9
.7
8
5
4
) 
Th
is
 p
a
p
er
 h
as
 b
ee
n
 p
ee
r-
re
vi
ew
ed
 a
n
d
 a
cc
e
p
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. T
h
e 
fi
n
al
 p
u
b
lis
h
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
observed (data not shown). In accordance to the reports from Santoro et al. (44) under the 
applied conditions, the reduction of the copper(II) complexes was incomplete, especially 
with nanomolar-active compounds (see plateau in Figure 3B and % non-reduced copper(II) 
complex after 1 h in Table 4). Interestingly, the remaining fraction of non-reduced 
copper(II) complex after 1 h (Table 4) showed a strong correlation with the pCu value and, 
therefore, with the solution stability of the copper(II) complexes (Figure 3C). These data 
demonstrate that the copper(II) complexes of α-N-pyridyl TSC ligands bearing higher 
solution stability can only be reduced by GSH in a slower and much less effective way. 
When these reduction rates were subsequently correlated with the anticancer activity 
(after 72 h), it became apparent that a slower reduction rate is associated with higher 
anticancer activity (Figure 3D and Suppl. Figure 6A) and paraptosis-inducing potential 
(Figure 3E and Suppl. Figure 6B) of the metal-free ligands as well as the copper complexes. 
Overall, these results are surprising, as so far it has been assumed that the anticancer 
activity of copper TSC complexes is mainly based on intracellular redox activity, either by 
the copper(II) TSC itself or by the copper release from the complex in the cell (22,44). 
Copper(II) complex stability influences redox behavior of TSCs under cell-free conditions 
It is widely accepted in the literature (22,27,38,44), that reduction of copper(II) complexes 
to copper(I) and their subsequent re-oxidation under aerobic conditions, results in the 
generation of superoxide radicals and thus redox stress in treated cells. In order to 
compare the obtained reduction rates of the copper(II) complexes by GSH to their 
superoxide production potential, formation of cell-free superoxide was measured 
spectrophotometrically using the nitroblue tetrazolium (NBT) assay. In line with the 
activation by reduction theory for this compound class (16), without the addition of a 
reducing agent, none of the tested TSCs (neither as metal-free ligand nor as copper(II) 
complex) induced any positive signal (data not shown). In contrast, as expected when the 
GSH precursor and reducing agent N-acetyl cysteine (NAC) was added to the copper(II) 
complexes, superoxide generation (up to 1.6-fold compared to the control) was detected 
(Figure 3F). In agreement with the above shown results, distinct differences between the 
individual ligands were observed. Thus, indeed copper(II) complexes with a higher stability 
and slower reduction rate produced also less cell-free superoxide (Figure 3G and Suppl. 
Figure 7). In contrast, copper ions, which under certain conditions have been reported to 
D
ow
nl
oa
de
d 
by
 N
or
th
w
es
te
rn
 U
ni
ve
rs
ity
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
5/
03
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 12 of 67 
 
 
 
12 
A
n
ti
o
xi
d
an
ts
 a
n
d
 R
e
d
o
x 
Si
gn
al
in
g
 
H
ig
h
 c
o
p
p
er
 c
o
m
p
le
x 
st
ab
ili
ty
 a
n
d
 s
lo
w
 r
e
d
u
ct
io
n
 k
in
et
ic
s 
as
 k
e
y 
p
ar
am
e
te
rs
 f
o
r 
im
p
ro
ve
d
 a
ct
iv
it
y,
 p
ar
ap
to
si
s 
in
d
u
ct
io
n
 a
n
d
 im
p
ac
t 
o
n
 d
ru
g
-r
e
si
st
an
t 
ce
lls
 o
f 
an
ti
ca
n
ce
r 
th
io
se
m
ic
ar
b
az
o
n
es
 (
D
O
I:
 
1
0
.1
0
8
9
/a
rs
.2
0
1
9
.7
8
5
4
) 
Th
is
 p
a
p
er
 h
as
 b
ee
n
 p
ee
r-
re
vi
ew
ed
 a
n
d
 a
cc
e
p
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. T
h
e 
fi
n
al
 p
u
b
lis
h
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
induce ROS on their own (10,41), did not result in positive measurable NBT signals (at 5 
µM) neither alone nor in combination with NAC (data not shown). Consequently, these 
data indicate that despite the widely accepted hypothesis that the anticancer activity of 
copper(II) complexes is based on (intracellular) reduction-induced ROS (superoxide) 
formation, in our hands especially the TSC complexes showing reduced redox activity are 
characterized by distinctly enhanced cytotoxicity.  
Stimulation of antioxidant enzymes and stress-response genes in TSC-treated cells 
In order to investigate, whether we can also detect superoxide production upon drug 
treatment in living tumor cells, the dihydroethidium (DHE) assay was used at conditions 
similar to the cell-free assay. Comparably to the results of the cell-free experiments, 
neither the ligands nor copper ions (5 µM) alone did significantly increase the fluorescence 
signals (data not shown). Unexpectedly, for the copper(II) complexes a different picture 
emerged compared to the cell-free experiments, as no significant increase in superoxide 
levels could be detected neither in presence nor in absence of NAC (Figure 4A). 
Hypothesizing that cancer cells efficiently protect themselves from TSC-induced redox 
stress by upregulation of antioxidant response signaling, we used our previously published 
(13) whole genome gene expression data of Triapine- and Me2NNMe2–treated SW480 
cells. In these experiments cells were treated either with Triapine (1 µM), Me2NNMe2 (0.1 
and 1 µM) or solvent for 15 h and mRNA levels were analyzed for drug-induced changes in 
gene transcription. When looking for altered gene sets associated with response to 
oxidative stress (e.g. “regulation of response to oxidative stress”) by gene set enrichment 
analysis (GSEA), no significant gene set enrichment was detected (lowest FDR values: 0.10 
for Me2NNMe2 and 0.35 for Triapine (Suppl. Figure 8)). However, when looking at 
individual genes, we found upregulation of the superoxide scavenger enzymes SOD2 and 
SOD3, but not SOD 1 upon Triapine treatment (Figure 4B). In contrast, in Me2NNMe2-
treated cells no comparable upregulation was observed for SOD2 (at IC50 concentrations) 
and SOD3 (Figure 4B). 
For confirmation at the protein level, Western blot analysis of SOD2 with lysates from cells 
treated with our TSC panel were performed. Indeed, SOD2 was upregulated after 
treatment with Triapine and all other micromolar-active TSCs, while none of the 
compounds with activity in the nanomolar concentration range induced SOD2 expression 
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(Figure 4C and D). To test whether SOD2 was also upregulated by Triapine treatment in 
tumor cells in vivo, CT-26 colon carcinoma-bearing mice were treated orally with either 
solvent or 10 mg/kg Triapine. As shown in Supp. Figure 10, Triapine had significant 
anticancer activity and was well tolerated in this setting. On the last day of treatment (day 
15), the tumors were collected and immunohistochemically stained for SOD2. In 
accordance with the array data as well as the Western blot analysis, also tumors from 
Triapine-treated animals showed strong stimulation of SOD2 expression compared to the 
solvent control (Figure 4E).  
Overall, the significant upregulation of SOD is in line with the hypothesis of efficient 
degradation of TSC-induced ROS and might explain the discrepancy of superoxide 
production between the cell-free and cell culture experiments observed above. Despite its 
much higher cytotoxicity, the SOD stimulation was weaker in case of Me2NNMe2 and the 
nanomolar-active TSCs, indicating that (in contrast to Triapine) at drug doses in the IC50 
range no significant generation of superoxide occurs in the treated cells with these 
compounds. Consequently, it can be hypothesized that due to the higher resistance of the 
copper(II) complexes towards reduction, the compounds are less efficient in ROS 
production inside of cells. 
Based on the assumed importance of metal chelation in the mode of action of TSCs, we 
also investigated changes in pathways regarding metal homeostasis in our arrays. 
Interestingly, we found only one significantly changed gene set, namely upregulation of 
genes involved in “response to zinc ions” after treatment with Me2NNMe2 (Figure 4F). This 
is of interest, as a closer look on this gene set revealed that, this gene set mainly contains 
metallothioneins (which are cysteine-rich, low molecular weight proteins being 
responsible also for copper homeostasis) as well as the copper transporters ATP7A and 
ATP7B (Figure 4G).  
High copper complex stability is important for PDI inhibition potential 
In a previous study, we showed that Me2NNMe2 induces paraptosis by inhibition of the ER-
resident PDI and consequent disruption of the ER thiol redox homeostasis (13). Therefore, 
the here studied copper-TSC complexes were tested for their potential to inhibit this 
enzyme. In line with our previous report (13), copper in form of a simple salt was already 
able to inhibit the PDI enzymes to some extent. This inhibition distinctly increased when 
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copper was complexed by Me2NNMe2 or other TSCs with terminal dimethylation/di-
substitution (Figure 5A). Interestingly, the inhibition followed an “all-or-nothing” pattern 
with complexes showing either the same weak inhibition as copper ions alone or strong 
PDI-disrupting ability comparable to the Me2NNMe2 complex. Dividing the compounds in 
these two categories, it can be clearly seen that PDI inhibition is associated with higher 
complex stability, higher anticancer activity and enhanced vesicle formation (Figure 5B and 
Suppl. Figure 11). Thus, although inhibition of the PDI is probably not the only target of the 
nanomolar-active TSCs (other targets may include the ribonucleotide reductase (RR) 
inhibition) (29,58), this indicates that there is a link between redox properties and copper 
complex stability with PDI inhibition and paraptosis induction, which needs to be further 
investigated in future studies.  
Discussion  
TSCs have long been known for their anticancer activity and their metal-chelating abilities 
(16,23). In case of the currently in phase III clinically investigated derivative Triapine, 
especially an interaction with the iron homeostasis was suggested based on its strong 
inhibition of the iron-containing ribonucleotide reductase and the occurrence of 
methemoglobinemia as the main adverse effect in patients (16). With the aim to develop 
TSCs with improved efficiency, derivatives with activity in the nanomolar IC50 range (such 
as DpC, Dp44mT and Me2NNMe2) came into the focus of interest during the last decade of 
which DpC also recently entered clinical trials (2,20,28,29). An increasing body of evidence 
indicates that these drugs have additional modes of action that are responsible for their 
increased cytotoxicity. The particularities of nanomolar-active TSC are indicated by the 
induction of 1) a specific form of ER stress associated with disruption of the ER thiol redox 
homeostasis and inhibition of the ER protein PDI (13,14,39,53), 2) a just recently 
discovered form of programmed cell death called paraptosis (13), and 3) increased activity 
in some multidrug-resistant cancer cells (9,40,46). Significantly, for all of these effects, the 
interactions with (intracellular) copper pools leading to formation of redox-active copper 
complexes were suggested to be crucial (16,19,34). Thus, it was proposed that copper 
complexes induce ROS (superoxide) by redox reaction with intracellular reductants, a 
mechanism also referred to as “activation by reduction” (11,34,36,44,49). Accordingly, a 
strong synergism between the metal-free ligand and free copper salts has been repeatedly 
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reported for nanomolar-active TSCs (19,28,49). However, the experiments supporting the 
ROS model were often performed either with preformed copper(II) complexes (11,34) or 
by preincubation of the ligands with high levels of extracellular copper (28,36,49). In 
contrast, in many cases, incubation with the metal-free ligands alone did not induce global 
ROS detectable for example by the DCF-DA stain (13,28,34). Thus, it might be hypothesized 
that, although there are indications that copper plays an important role in the mode of 
action of nanomolar-active TSCs, under physiological conditions, this might not be due to 
reductant-induced global redox stress production. However, localized and slower non-
ROS-producing redox reactions (e.g. formation of disulfide bridges) might still be involved 
in their activity.  
The aim of this study was to further investigate the role of copper in the activity of 
nanomolar-active TSCs in comparison to micromolar-active derivatives such as Triapine. To 
this end, a selected panel of structurally related α-N-heterocyclic TSCs and their respective 
copper(II) complexes was investigated with regard to solution stability, cell-free as well as 
intracellular redox properties, toxicity against sensitive and MDR cancer cell lines and 
paraptosis-inducting potential. We show that the activity of the compounds has a strong 
correlation with these properties, confirming the relevance of their interaction with 
copper ions (Figure 5C). 
To analyze the interaction of the compounds with copper in more detail, we compared the 
anticancer activity of the preformed copper complexes with that of the metal-free ligands, 
together with their potential to induce collateral sensitivity in a P-gp-overexpressing cell 
model. Thereby, crucial differences were observed between short- and long-term drug 
incubation. While short incubation times (3 and 24 h) resulted in higher anticancer activity 
for especially nanomolar-active TSC copper(II) complexes compared to metal-free ligands, 
after longer incubation times (72 and 144 h), mostly no enhanced efficiency of the copper 
complexes was observed. The increased activity is in line with the literature showing 
(mainly for the nanomolar-active compounds) an enhanced activity of the metal-free 
ligands when co-applied with an excess of simple copper salts (19,28,49) or of preformed 
1:1 or 1:2 copper(II):Dp44mT complexes compared to the metal-free ligand (20). An 
exception to the increased activity were copper(II) complexes of Triapine, H2NNHMe and 
H2NNMe2, which showed no activity after short-time and even lower activity compared to 
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the metal-free ligand after long-term incubation. This may be explained by a less efficient 
absorption and cellular uptake of the charged [CuL]+ species compared to the neutral HL 
ligand which are the predominating forms in solution at physiological pH based on our 
solution speciation studies in all cases. After longer incubation times, the differences in 
activity between the copper(II) complexes and the respective metal-free ligands 
disappeared which could be explained by the hypothesis of different kinetics of the 
underlying cell killing mechanisms as described by  Ishiguro et al. (19). Thus, while the 
rapid cell killing mechanism is conducted by extracellular TSC copper complexes and 
characterized by redox reactions (27), the slow activity is redox-independent and depends 
more on the ligand and/or intracellular copper complexation. In this regard, MES-SA/Dx5 
cells were found to be more resistant against the rapid cell killing mechanism of both the 
metal-free ligands and preformed complexes compared to the parental MES-SA cells (seen 
in the 24 h IC50 values), while they were (slightly) more sensitive to the long-term activity 
of most copper complexes compared to the respective ligands. The exception were 
complexes of TSCs such as Triapine, H2NNMeH and H2NNMe2, with lower activity 
compared to metal-free ligands, that also did not exhibit increased activity in MES-SA/Dx5 
cells as either ligand or complex. In fact, collateral sensitivity of MES-SA/Dx5 cells 
correlated with higher copper(II) complex stability, which further points to the importance 
of copper chelation for nanomolar TSC activity. This is in good agreement with previous 
studies, as also P-gp-overexpressing and Triapine-resistant SW480 or colchicine-resistant 
KB-3-1 cells showed no cross-resistance against terminally or pyridine amino di-substituted 
(especially nanomolar) TSCs after long-term incubation (28,52). 
It is important to note that the copper(II) complexes of the studied TSC ligands have the 
same composition ([CuL]+) with the same coordination mode (Npyridyl,N,S
−)(H2O) at pH 7.4 
in aqueous solution. However, significant differences were seen regarding their stability. 
Namely, the nanomolar-active TSCs form complexes of significantly higher stability with 
this metal ion compared to the micromolar compounds. On the other hand, the copper(II) 
complexes of the nanomolar TSCs could be reduced by GSH in a much slower redox 
reaction. When we investigated the role of redox activity, opposing to the current theory 
of activation by reduction (16,20,27), nanomolar-active TSCs were characterized by 
copper(II) complexes with higher stability and less efficient reduction by reducing agents.  
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This observation is in line with other studies such as from Garcia-Tojal et al., and from 
Santoro et al. who both found slower reduction by GSH in the case of the copper(II) 
complex of Dp44mT, as compared to the copper(II) complexes of Triapine and FTSC/PTSC 
(11,44). Moreover, for both Triapine as well as FTSC, reduction of the copper(II) complex 
resulted in efficient binding of the copper(I) ion to GSH leaving a metal-free ligand able to 
interact with other metal ions such as iron or zinc (44). In agreement with a slower 
reduction, also cell-free superoxide production (which results from re-oxidation of the 
copper(I) complex) was lower with these complexes. Interestingly, the confirmation of 
these data in living cells turned out to be difficult. Thus, at physiologically relevant 
conditions, none of the TSC complexes increased DHE fluorescence (indicating intracellular 
superoxide) neither in presence of a thiol-containing reducing agent (NAC) nor in its 
absence. Consequently, we hypothesized that cells rapidly adapt to redox stress and 
efficiently degrade the drug-generated superoxide.  
In line with a higher, cell-free superoxide production of Triapine and its closest 
(micromolar-active) derivatives, upregulation of the superoxide-degrading enzymes 
SOD2/3 on mRNA and protein levels was identified as a possible protection mechanism. 
This is of interest as comparable upregulation and increased activity of SOD enzymes was 
also reported and shown to protect against treatment with TSC copper complexes by other 
groups (11,48,51). This stimulation of SODs only in case of micromolar-active TSCs led us to 
the theory that in case of Triapine and its close derivatives, the rather fast (intracellular) 
reduction leads to rapid dissociation of the copper complex and thus liberation of the 
metal-free ligands (which is also in good agreement with the very recently published data 
of Santoro et al. (44)). Consequently, metal-free (or iron-/zinc-bound) Triapine could be 
the main species occurring inside the cell, playing a primary role in anticancer activity. In 
contrast, as copper(II) complexes of nanomolar-active TSCs are much slower in their 
reduction and thus more stable, the copper(II) complex is able to reach intracellular 
targets such as the ER-resident protein PDI (Figure 5D). In line with this hypothesis, 
paraptosis induction, measured by vacuole formation, was most pronounced with the 
nanomolar-active TSCs. This increase in paraptosis induction also correlated with the 
solution stability of their copper complexes as well as a slower reduction rate. In addition, 
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also PDI inhibition by the TSC complexes highly correlated with copper complex stability 
and vacuole formation.  
In line with a more pronounced role of copper in the anticancer activity of nanomolar-
active TSCs, our array analysis revealed that Me2NNMe2 induces upregulation of 
metallothioneins, which strongly bind diverse metal ions including copper(I). Noteworthy, 
metallothioneins also contain multiple thiol groups, and thus take part in the cellular thiol 
redox homeostasis (43), which seems to be disrupted by the nanomolar-active TSC copper 
complexes (13). Interestingly, it has been suggested by Santoro et al. that metallothioneins 
play a crucial role in the removal of the reduced copper(I) from Triapine and FTSC after 
reduction, while in case of Dp44mT the interaction of zinc-loaded metallothioneins with 
the copper(I)-TSC-GSH complex resulted in zinc transmetalation (44). In accordance, also 
our data indicate that there might be an interaction with metallothioneins also in the 
cytosol (but not in the ER) of living cells after treatment with the metal-free TSC ligand. 
The exact nature of this interaction definitely warrants further investigations. 
Innovation (100 words) 
In conclusion, the here presented work on the one hand, confirms that interaction with 
copper ions plays an important role in the anticancer activity of nanomolar-active TSCs. On 
the other hand, it also raises strong doubts on the dogma of “activation by reduction”-
induced redox stress via superoxide production as main executer of (metal-free applied) 
drug effectivity. In contrast, we propose that due to their high solution stability, copper(II) 
complexes of nanomolar-active TSCs are able to reach additional intracellular protein 
targets such as the ER-resident PDI resulting in paraptotic cell death induction and 
increased anticancer activity. 
Materials and Methods 
Chemicals 
FTSC, PTSC, Triapine, H2NNHMe, H2NNMe2, MeHNNMe2, Me2NNH2, Me2NNHMe, 
Me2NNMe2, FTSC, MeHNNH2, MeHNNHMe, Dp44mT and DpC were prepared as described 
previously (28,29,35). Ethylenediaminetetraacetic acid (EDTA), KCl, KOH, HCl was obtained 
from Reanal (Hungary), 2-(N-morpholino)ethanesulfonic acid (MES) and 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) was purchased from Sigma-Aldrich 
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and used without further purification. Copper(II) stock solution was prepared by the 
dissolution of CuCl2 in water and its concentration was determined by complexometry with 
EDTA. For cell culture experiments TSCs were first diluted in DMSO (10 mM) after which 
further dilutions were performed in aqueous solutions (double distilled (dd) H2O, buffer or 
cell culture media depending on the assay) or with which copper complexes were formed 
in combination with CuCl2 (10 mM in ddH2O). Thereby, concentrations of DMSO in cell 
culture did not reach toxic doses. For spectrophotometric measurements, TSCs were 
directly diluted in ddH2O at low concentrations (255 µM) and dissolution was improved by 
ultrasound bath and adding low concentration of HCl. 
Spectrophotometric titrations 
A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV-Vis 
spectra in the interval 200–800 nm. The path length was 1 cm. Proton dissociation 
constants (pKa) of the TSC ligands, the copper(II) mono complexes and the individual 
spectra of the species in the various protonation states were calculated by the computer 
program PSEQUAD (31). Spectrophotometric titrations were performed on samples 
containing the ligands at 10-50 µM concentration by a KOH solution in the presence of 0.1 
M KCl at 25.0 ± 0.1 oC in the pH range from 2 to 11.9. An Orion 710A pH-meter equipped 
with a Metrohm combined electrode (type 6.0234.100) and a Metrohm 665 Dosimat 
burette were used for the pH-metric titrations. The electrode system was calibrated to the 
pH = -log[H+] scale by means of blank titrations (HCl vs. KOH) according to the method 
suggested by Irving et al. (18). The average water ionization constant (pKw) is 13.76 ± 0.05 
in water. Argon was also passed over the solutions during the titrations. 
Due to the limited water solubility of DpC pKa values of the ligand were determined in 5 
and 30% (w/w) DMSO/H2O solvent mixture, while pKa values of the copper(II) complexes in 
30% (w/w) DMSO/H2O. The pKa values obtained at various DMSO content were plotted 
against the 1/εr values of the solvent medium, where εr is the relative permittivity (or 
dielectric constant) of the solvent medium and values for the pure aqueous solution were 
obtained by extrapolation. The εr values are interpolated data taken from (4). Namely, the 
pKa values for DpC in pure water were extrapolated from the values obtained in the 
DMSO/H2O mixtures with the slopes of the linear curves of DpC (5%, 30%), Triapine (0%, 
30%) and H2NNMe2 (0%, 30%).  
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The conditional stability constants (β’) of the copper(II) complexes were calculated at pH 
5.90 based on the spectral changes via the displacement reaction with EDTA in the 
presence 50 mM MES and 0.1 M KCl (using 1-2 h incubation). Data for pKa of EDTA and its 
Cu(II) complex taken from (8) and log’5.90  = 13.89 was calculated for [Cu(EDTA)]
2-. In the 
competition experiments the samples contained 25 µM copper(II), 25 µM ligand and the 
concentration of EDTA was varied in the range from 0 to 400 µM. It should be noted that 
EDTA and its copper(II) complex have negligible contribution to the measured absorbance 
values in the monitored wavelength range (320-550 nm), only [CuL]+ and HL absorb light. 
In the case of DpC and Triapine the completion reaction was performed in 30% (w/w) 
DMSO/H2O solvent mixture. The conditional stability constants of the metal complexes (β' 
(CuL)) and the individual spectra of the species were calculated by the computer program 
PSEQUAD (31). The overall stability constants of the [CuL]+ complexes (β) were calculated 
from the conditional stability constants: β [CuL]+ = β' [CuL]+ × αH, where αH = 1 + [H
+]/Ka 
(HL) + [H+]2 / (Ka (HL) × Ka (H2L
+)); [H+] = 10‒5.90 M. The overall stability constants of the 
protonated [CuLH]2+ and the mixed hydroxido [CuL(OH)] complexes were calculated as 
follows: log β [CuLH]2+ = log β [CuL]+ + pKa [CuLH]
2+. Log β [CuL(OH)] = log β [CuL]+ ‒ pKa 
[CuL]+. pCu = −log [Cu(II)] values were calculated at pH 7.4 using the determined stability 
constants. 
Spectrophotometric kinetic measurements 
The redox reaction of the copper(II) complexes with GSH and AA was studied at 25.0 ± 0.1 
oC on Hewlett Packard 8452A diode array spectrophotometer using a special, tightly closed 
tandem cuvette (Hellma Tandem Cell, 238-QS). The reactants were separated until the 
reaction was triggered. Both isolated pockets of the cuvette were completely 
deoxygenated by bubbling a stream of argon for 10 min before mixing the reactants. 
Spectra were recorded before and then immediately after the mixing, and changes were 
followed till no further absorbance change was observed. One of the isolated pockets 
contained the reducing agent (GSH or AA) and its concentration was in the range of 250-
2500 µM and the other contained the copper(II) complex, which was prepared in situ using 
25 µM of the metal ion and the ligand respectively. The pH of all the solutions was 
adjusted to 7.40 by 50 mM HEPES buffer and an ionic strength of 0.1 M (KCl) was applied. 
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The stock solutions of the reducing agents and the complexes were freshly prepared every 
day.  
During the calculations the absorbance (A) ‒ time (t) curves were fitted and analyzed at 
the λmax of the complex. (A0‒Afinal) × e
(‒a×t) + Afinal equation was used where A0, Afinal and a 
parameters were refined and accepted at the minimal value of the weighted sum of 
squared residuals (difference between the measured and calculated absorbance values) at 
the given wavelength. Then observed rate constants (kobs) of the redox reaction were 
obtained from the data points of the simulated absorbance-time curves as the slope of the 
ln(A/A0) versus t plots.  
Cell lines and culture conditions  
Human uterine sarcoma MES-SA and the doxorubicin selected MES-SA/Dx5 cells 
expressing mCherry and eGFP proteins, respectively, were engineered from MES-SA and 
MES-SA/Dx5 (ATCC; MES-SA: No. CRL-1976™, MES-SA/Dx5: No. CRL-1977™) using a 
lentiviral system (55). The phenotype of the resistant cells was verified using cytotoxicity 
assays (not shown). Prior to the experiments, MES-SA/Dx5 cells were cultured in 500 
nmol/L doxorubicin, to ensure Pgp expression. Cells were cultured in DMEM (SigmaAldrich, 
Hungary) supplemented with 10% fetal bovine serum, 5 mmol/L glutamine, and 50 
units/ml penicillin and streptomycin (Life Technologies). Human colorectal 
adenocarcinoma SW480 cells (obtained from ATCC; No. CCL-228™) were cultured in MEME 
supplemented with 10% fetal calf serum (PAA, Austria). CT-26 murine colon carcinoma 
cells (CRL-2638, purchased from ATCC) were cultured in Dulbecco's modified eagle's 
medium (DMEM)/F12 medium (1:1 from Sigma; #D6421) supplemented with 10% heat-
inactivated fetal calf serum. All cell lines were cultivated at 37 °C, 5% CO2. 
Cell viability assay 
In the co-culture system, after trypsinization, suspensions of MES-SA mCherry and MES-
SA/Dx5 eGFP cells were mixed, and seeded on 384-well plates at a 2500 cells/well density 
(1250 cells/well per cell model) in 20 μl of medium, one day prior to drug addition. Cells 
were then treated with a serial dilution of the drugs, so that the final volume was 60 μl. 
Liquid handling was fully automated by a Hamilton StarLet robotic pipetting workstation 
(Hamilton, Switzerland). Plates were incubated, and measured twice: after 72 and 144 h of 
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drug addition. Growth inhibition of the cells was assessed based on the detection of the 
respective fluorescent intensities scanned from the wells by an EnSpire plate reader (eGFP: 
485ex/510em; mCherry: 585ex/610em, Perkin Elmer, UK). Raw measurement files were 
exported, and automated data evaluation was performed by our custom program, which 
was written by Judit Sessler in C#. Data was normalized to the negative (live cells, maximal 
fluorescence) and positive (dead cells, minimal fluorescence) controls, then growth 
inhibition data points (plotted against the respective concentrations) were connected with 
a line, and IC50 was considered as the point, at which the connecting line reached the 50% 
inhibition according to the Y axis.  
For single cell viability assay, SW480 cells were plated (2 x 103 cells/well) in 96-well plates 
and allowed to recover for 24 h. Then, cells were treated with increasing concentrations of 
TSCs for 72 h. Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)-based vitality assay (EZ4U; Biomedica, Vienna, Austria) 
as published (17). GraphPad Prism software was used to calculate cell viability expressed 
as IC50 values calculated from full dose-response curves. For further analysis and 
comparison, pIC50 values were used instead of IC50 values (Suppl. Figure 1). pIC50 values 
were calculated as the –log10 from IC50 values in molar. 
Microscopy 
Cells were seeded into a 24-well plate with 2 x 104 cells/well and left to recover for 24 h. 
Then, cells were treated with indicated concentrations of TSC ligands. After 24 or 48 h, 
microscopic phase-contrast images were taken with a Zeiss primo vert microscope with a 
Zeiss axio cam ERc5s camera. Percentage of vacuolated cells was counted in at least three 
different parts of a well. 
Quantification of superoxide radicals 
To examine the cell-free production of superoxide radicals, the reduction of NBT was 
analyzed as previously reported (27) . Briefly, 0.6 mM NBT was incubated with 5 μM 
copper(II) complexes with or without 2 mM NAC. The experiments were performed in PBS 
(pH 7.4). The extent of NBT reduction was determined spectrophotometrically by 
measuring the absorbance at 560 nm after 45 min of incubation. No superoxide radicals 
were observed without NAC (data not shown). 
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Intracellular superoxide determination using DHE 
DHE (#D7008, Sigma-Aldrich, MO, USA) was used to detect the production of intracellular 
superoxide. Briefly, 5 × 105 MES-SA cells per sample in 500 μl of PBS (78.1 mM Na2PO4 x 2 
H2O, 14.7 mM KH2PO4, 26.8 mM KCl, 1.37 M NaCl) were incubated with or without 2 mM 
NAC for 15 min at 37°C. Then, 5 µM of indicated TSC complexes were added for further 60 
min. Subsequently, DHE (10 µM) was added 30 min before measurement. After incubation, 
the mean fluorescence intensity was measured by flow cytometry using a FACSCalibur 
instrument (Becton Dickinson, Palo Alto, CA, USA). Antimycin A (AMA, 10 µM) was used as 
positive control. 
PDI reduction activity measurement 
PDI reduction activity was measured using PROTEOSTAT PDI assay kit (#ENZ-51024, Enzo 
Life Sciences, Switzerland). Experiments were performed according to the manufacturer's 
instructions. Briefly, drugs alone or preincubated with CuCl2 (1:1) were added to a 
prepared insulin PDI solution. Then, dithiothreitol (DTT) (1 mM) was added to start PDI 
reduction activity. After 30 min the reaction was stopped by the Stop reagent and the 
insulin precipitate was fluorescently labeled with Proteostat PDI detection reagent for 15 
min. Fluorescence intensity was measured at 500 nm excitation and 603 nm emission 
using the spectrophotometer Tecan infinite 200Pro (Tecan Group, Männedorf, 
Switzerland).  
Protein expression 
After drug treatment, total protein lysates were prepared, 20 µg per sample separated by 
SDS-PAGE and transferred onto a polyvinylidene difluoride membrane for Western blotting 
as described previously (17). The following antibodies were used: Cell Signaling Technology 
(MA, USA): SOD2 (#13141), GAPDH (#5174). Primary antibodies were used 1:1000. 
Secondary anti-rabbit (#7074) horseradish peroxidase-labeled antibodies from Cell 
Signaling Technologies were used in working dilutions of 1:10 000. 
Total-RNA isolation and whole genome gene expression array 
Total RNA from SW480 cells (either untreated or treated (0.1 or 1 µM for 15 h)) was 
isolated using RNeasy Mini kit (#74106, Quiagen, Germany) following the manufacturer’s 
instruction. Transcriptional profiles of cells were determined performing a 4 × 44K whole 
genome oligonucleotide gene expression array (Agilent, California, US) as described 
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previously (32). Normalization was performed in R using the Bioconductor (version 3.7) 
package “limma” if not otherwise indicated (42). Whole genome gene expression array 
and gene set enrichment analysis (GSEA) were performed as previously described (13).  
Animal experiments 
Six- to eight-week-old BALB/c mice were purchased from Janvier (France). The animals 
were kept in a pathogen-free environment and every procedure was done in a laminar 
airflow cabinet. Experiments were done according to the regulations of the Ethics 
Committee for the Care and Use of Laboratory Animals at the Medical University Vienna 
(proposal number BMWF-66.009/0081-WF/V/3b/2015), the U.S. Public Health Service 
Policy on Human Care and Use of Laboratory Animals as well as the United Kingdom 
Coordinating Committee on Cancer Prevention Research's Guidelines for the Welfare of 
Animals in Experimental Neoplasia. To ensure animal welfare throughout the experiment, 
the body weight of the mice was assessed once a day. At weight loss exceeding 10 % (in 
less than two days) or occurrence of ascites, animals were sacrificed by cervical 
dislocation.  
In vivo analysis of SOD2 expression 
CT-26 cells (5x105 cells in 50 µl) were injected subcutaneously into the right flank of female 
Balb/c mice. Starting on day 4, Triapine (10 mg/kg in 10% DMSO) or solvent treatment was 
given orally for 5 consecutive days a week for two weeks. Animals were sacrificed on 
indicated days per cervical dislocation and tumor tissue was isolated and fixed in 4% 
paraformaldehyde (Carl Roth, #P087.3) for 24 h. Tumor tissue was paraffin-embedded 
with the KOS machine (Milestone) and sliced in 4 µm thick sections. For SOD2 staining, 
sections were incubated with a SOD2-specific antibody (1:1000, Cell Signaling, #13141) in a 
humid chamber for 1 h at room temperature after antigen retrieval by boiling for 30 min in 
10 mM citrate buffer (pH 6.0, DAKO; #S1699),. Antibody binding was detected using the 
UltraVision LP detection system according to the manufacturer's instructions (Thermo 
Fisher Scientific Inc.; #TL-125-HL). Color was developed using 3,3′-diaminobenzidine (Dako; 
#K3468), followed by a nuclear counterstain with hematoxylin. Stained tissue slides were 
scanned and analyzed using Definiens Software. 
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Correlation analysis 
Correlations were performed in the GraphPad Prism 8 software. R2 from linear or one 
phase decay regression are given in correlation diagrams. Regressions lines are shown in 
correlation plots with 95% confidence interval. P-values were calculated using Pearson 
correlation coefficient which is a measure of linear correlation. For the correlation matrix 
(Figure 6D) p-values of correlations were corrected for multiple comparisons with two-
stage linear step-up procedure of Benjamini, Krieger and Yekutieli with a false discovery 
rate (FDR) of 1%. The thereby generated q-values are shown with a greyscale code. 
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List of Abbreviations 
AA – ascorbic acid 
AMA – antimycin A 
dd – double distilled 
DHE - dihydroethidium 
DMSO – dimethyl sulfoxide 
Dp44mT - di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone 
DpC – di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone 
DTT – dithiothreitol 
EDTA – ethylenediaminetetraacetic acid 
ER – endoplasmic reticulum 
FDR – false discovery rate 
FTSC - 2-formylpyridine thiosemicarbazone  
GSEA – gene set enrichment analysis 
GSH – glutathione 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
MDR – multidrug resistant 
MES - 2-(N-morpholino)ethanesulfonic acid 
MT – metallothionein 
MTT - 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAC – N-acetyl cysteine 
NBT- nitroblue tetrazolium 
PDI – protein disulfide isomerase 
P-gp – P-glycoprotein (ABCB1) 
PTSC - pyridine-2-carbaldehyde thiosemicarbazone 
RR – ribonucleotide reductase 
ROS – reactive oxygen species 
SOD – superoxide dismutase 
TSC – thiosemicarbazone 
UV-vis – UV-visible 
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Table 1: Structure and IC50 (72 h) values of tested compounds in SW480 cells. 
Compound Structure TSC IC50 (µM) Cu-TSC IC50 (µM) 
FTSC 
 
6.54 ± 0.22 6.01 ± 0.54 
PTSC 
 
0.051 ± 0.025 0.057 ± 0.024 
Triapine 
 
0.68 ± 0.18 1.19 ± 0.61 
H2NNHMe 
 
2.54 ± 0.61 3.13 ± 1.48 
H2NNMe2 
 
0.80 ± 0.12 1.62 ± 0.28 
MeHNNMe2 
 
2.28 ± 0.17 3.30 ± 0.83 
Me2NNH2 
 
8.51 ± 1.18 4.97 ± 1.57 
Me2NNHMe 
 
7.80 ± 2.06 0.93 ± 0.38 
N
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NH2
N
N
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Me2NNMe2 
 
0.038 ± 0.012 0.066 ± 0.020 
Dp44mT 
 
0.047 ± 0.018 0.034 ± 0.013 
DpC 
 
0.043 ± 0.017 0.039 ± 0.012 
 
  
N
N
N
H
S
N
N
N
N
N
H
S
N
N
N
N
N
H
S
N
N
D
ow
nl
oa
de
d 
by
 N
or
th
w
es
te
rn
 U
ni
ve
rs
ity
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
5/
03
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 37 of 67 
 
 
 
37 
A
n
ti
o
xi
d
an
ts
 a
n
d
 R
e
d
o
x 
Si
gn
al
in
g
 
H
ig
h
 c
o
p
p
er
 c
o
m
p
le
x 
st
ab
ili
ty
 a
n
d
 s
lo
w
 r
e
d
u
ct
io
n
 k
in
et
ic
s 
as
 k
e
y 
p
ar
am
e
te
rs
 f
o
r 
im
p
ro
ve
d
 a
ct
iv
it
y,
 p
ar
ap
to
si
s 
in
d
u
ct
io
n
 a
n
d
 i
m
p
ac
t 
o
n
 d
ru
g-
re
si
st
an
t 
ce
lls
 o
f 
an
ti
ca
n
ce
r 
th
io
se
m
ic
ar
b
az
o
n
es
 (
D
O
I:
 
1
0
.1
0
8
9
/a
rs
.2
0
1
9
.7
8
5
4
) 
Th
is
 p
a
p
er
 h
as
 b
ee
n
 p
ee
r-
re
vi
ew
ed
 a
n
d
 a
cc
e
p
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. T
h
e 
fi
n
al
 p
u
b
lis
h
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
Table 2: IC50 (72 h) values of tested compounds in MES-SA and MES-SA/Dx5 cells. 
 
  
 
TSC IC50 (µM) Cu-TSC IC50 (µM) 
 
MES-SA 
MES-SA/Dx5 
(resistance factor) 
MES-SA 
MES-SA/Dx5 
(resistance factor) 
FTSC 1.87 ± 0.22 8.11 ± 0.94 (4.3) 9.45 ± 0.49 4.31 ± 0.72 (0.46) 
PTSC 0.129 ± 0.032 0.029 ± 0.003 (0.22) 0.081 ± 0.046 0.024 ± 0.005 (0.30) 
Triapine 0.63 ± 0.09 2.58 ± 0.33 (4.1) 2.44 ± 0.47 16.86 ± 2.15 (6.9) 
H2NNHMe 0.86 ± 0.10 4.05 ± 0.39 (4.7) 6.75 ± 1.31 21.35 ± 3.35 (3.2) 
H2NNMe2 0.51 ± 0.13 0.76 ± 0.17 (1.5) 2.57 ± 0.47 4.19 ± 0.24 (1.6) 
MeHNNMe2 0.99 ± 0.12 2.76 ± 0.00 (2.8) 6.22 ± 1.43 2.13 ± 0.47 (0.34) 
Me2NNH2 3.51 ± 0.55 3.29 ± 0.74 (0.94) 9.91 ± 1.22 3.24 ± 0.29 (0.33) 
Me2NNHMe 2.57 ± 0.31 2.24 ± 0.51 (0.87) 3.58 ± 0.97 1.13 ± 0.13 (0.32) 
Me2NNMe2 0.013 ± 0.002 0.004 ± 0.001 (0.31) 0.030 ± 0.018 0.008 ± 0.002 (0.27) 
Dp44mT 0.029 ± 0.015 0.006 ± 0.001 (0.21) 0.066 ± 0.039 0.004 ± 0.001 (0.06) 
DpC 0.034 ± 0.027 0.003 ± 0.002 (0.09) 0.009 ± 0.007 0.001 ± 0.0008 (0.11) 
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Table 3: pKa values of the TSC ligands determined by spectrophotometric titrations and 
overall stability constants for the copper(II) TSC complexes (logβ) * calculated from the 
conditional stability constants (logβ’5.9 of [CuL]
+) and pKa values of the copper(II) 
complexes. pCu = −log *Cu(II)+ values calculated at pH 7.4 cCu(II) = cTSC = 1 µM and fraction of 
[CuL(OH)]. 
ligand mediu
m 
pKa 
(H2L
+
) 
pKa (HL) logβ 
[CuLH]2
+ 
logβ 
[CuL]
+ 
logβ 
[CuL(OH)
] 
pCu % 
[CuL(OH)
] 
FTSC H2O 3.48
± 
0.01 
10.72±0.0
1 
20.34 18.26 9.56 11.9
6 
4.8 
PTSC H2O 3.61
± 
0.01 
10.22±0.0
1 
21.05 18.96 10.40 13.1
7 
6.5 
Triapine * H2O 4.25 10.58 20.08 17.57 8.93 11.3
5 
5.4 
H2NNHMe H2O 4.40
± 
0.01 
11.03±0.0
1 
20.26 17.72 9.10 11.1
2 
5.7 
H2NNMe2 H2O 4.64
± 
0.01 
10.09±0.0
1 
20.84 18.33 9.68 12.6
6 
5.3 
MeHNNMe
2 
H2O 4.87
± 
0.01 
9.87±0.01 20.80 18.16 9.97 12.7
5 
14.0 
Me2NNH2 H2O 4.43 10.87±0.0 20.56 18.25 9.72 11.8 6.9 
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± 
0.01 
1 1 
Me2NNHM
e 
H2O 4.53
± 
0.02 
10.98±0.0
7 
21.02 18.45 10.34 11.9
5 
16.3 
Me2NNMe2 H2O 4.93
± 
0.01 
10.69±0.0
1 
22.06 19.55 10.77 13.2
8 
4.0 
Dp44mT  H2O 3.44
± 
0.01 
10.44±0.0
1 
21.77 19.43 10.64 13.4
1 
3.9 
DpC 5% 
DMSO 
3.47
± 
0.01 
10.71±0.0
1 
- - - - - 
DpC 30% 
DMSO 
3.03
± 
0.06 
11.38±0.0
6 
19.28 17.15 7.69 10.1
7  
0.9  
DpC † H2O 3.50 10.67 22.81 20.36 12.00 14.1
3 
9.9 
Triapine ‡ 30% 
DMSO 
3.92 10.78 16.69 14.35 4.68 8.55 0.5 
H2NNMe2
 ‡ 30% 
DMSO 
4.31 10.29 17.05 15.12 5.63 9.38 0.8 
* pKa taken from Ref. (20). 
† Estimated values from the pKa values of DpC ligand measured 
in 5% and 30% (w/w) DMSO/H2O mixtures. 
‡ Data taken from Ref.(5).  
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Table 4: Calculated observed rate constants (kobs) and half-lives (t1/2) in the copper(II) – TSC 
– GSH (1:1:50) systems from the spectral changes at the λmax of the copper(II) complex and 
absorbance values measured at 1 h compared to that of the ligand.  
 kobs (min
‒1) t1/2 (min) λ (nm) fraction of non-
reduced Cu(II)-
complex at 1 h (%) 
FTSC 4.13×10‒2 17 380 10 
PTSC* 4.30×10‒4 1615 394 90 
Triapine † 1.10×10‒1 6 420 4 
H2NNHMe 7.70×10
‒2 9 420 10 
H2NNMe2  1.60×10
‒2 44 424 61 
MeHNNMe2 1.12×10
‒2 62 450 57 
Me2NNH2 4.47×10
‒2 16 416 24 
Me2NNHMe 3.90×10
‒2 18 420 20 
Me2NNMe2 6.97×10
‒4 1019 422 92 
Dp44mT 2.12×10‒3 329 412 80 
DpC 2.30×10‒3 298 422 85 
FTSC 4.13×10‒2 17 380 10 
PTSC† 4.30×10‒4 1615 394 90 
* kobs = 1.03×10
‒3 min‒1, t1/2 = 675 min in the presence of 100 eq. GSH (20). 
† kobs = 6.30×10
‒
2 min‒1, t1/2 = 11 min in the presence of 20 eq. GSH; kobs = 5.90×10
‒2 min‒1, t1/2 = 12 min in 
the presence of 10 eq. GSH.  
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Figure Legends 
 
Figure 1: Change of anticancer activity upon complexation with copper(II) and potential 
of the tested TSC panel to induce paraptosis. A: Differences of logarithmic anticancer 
activity of the metal-free ligand to the respective copper in the indicated cell lines complex 
[pIC50(TSC) - pIC50(Cu-TSC)]. IC50 values were determined in mono- or co-culture as 
described in the Materials and Methods section after 72 h. B: Fold resistance of MES-
SA/Dx5 compared to MES-SA cells against either the metal-free TSCs or the respective 
copper(II) complexes (Cu-TSC). C: Representative microscopy images of SW480 cells 
treated with 1 µM of the indicated metal-free TSCs for 24 h. Arrows indicate the 
cytoplasmic vesicles. Scale bar: 100 µm. The graph on the right shows the percentage of 
cytoplasmic vesicles observed after treatment of SW480 cells with 0.1 or 1 µM metal-free 
TSC for 24 h. Values given are mean ± standard deviation of three areas per well of two 
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independent experiments. Line indicates 10% threshold of vesicle induction. D: Metal-free 
compounds inducing vesicles (threshold: 10%) at 1 µM in SW480 cells also showed a higher 
anticancer activity in the nanomolar range [pIC50 = -log(IC50)]. Significance between groups 
was calculated using T-test by two-tailed t-test using GraphPad Prism software (** p < 
0.01). Open symbols indicate nanomolar-active TSCs. 
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Figure 2: Higher copper(II) complex stability correlates with increased anticancer activity. 
A: UV-vis spectra of Me2NNMe2 (40 µM) recorded at pH values between 2 and 11.9 and 
scheme for stepwise deprotonation of metal-free TSCs. B: UV-vis spectra of the copper(II) 
complex of Me2NNH2 (25 µM) recorded at pH values between 2 and 11.5 and scheme of 
stepwise deprotonation of TSC copper(II) complexes. C: Speciation curves of Cu-Triapine 
system depending on pH. D: UV-vis spectra of the copper(II) complex of Me2NNMeH (25 
µM) in the presence of EDTA at various ratios (EDTA to complex, cEDTA = 0-175 µM) and the 
spectrum of the metal-free Me2NNMeH (grey dashed line) at pH 5.9. E: Correlation of pCu 
[-log(Cu(II))] values, representing copper(II) complex stability, to anticancer activity (pIC50 
values) of the TSC copper complexes in MES-SA cells. R2 and p values have been calculated 
using Graph Pad Prism software. F: Correlation of pCu to the logarithmic resistance factor 
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to the metal-free TSCs of MES-SA/Dx5 cells compared to parental MES-SA cells. R2 and p 
values have been calculated using Graph Pad prism software. G: Grouping of the 
compounds by vesicle induction (threshold: 10%) at 1 µM treatment metal-free ligand of 
SW480 for 24 h or MES-SA cells for 48 h showed a higher complex stability in vesicle-
inducing TSCs. Significance between groups was calculated by two-tailed T-test using 
GraphPad Prism software (*** p < 0.001, * p < 0.05). Open symbols indicate nanomolar-
active TSCs. 
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Figure 3: Cell-free reduction rate and superoxide production of copper(II) complexes and 
their correlation with biological activity. A: Time dependence of the UV-vis spectra of the 
MeHNNMe2 copper(II) complex (25 µM) in the presence of 50 equivalents GSH (1.25 mM) 
and the spectrum of the metal-free ligand (dashed line) at pH 7.4 under O2-free condition. 
B: Decrease of absorbance (in % A/A0) recorded at λmax of the different copper(II) TSC 
complexes over time at the same conditions given in A. Symbols: Triapine (■), H2NNHMe 
(♦), FTSC (▲), Me2NNHMe (●), Me2NNH2 (▲), MeHNNMe2 (♦), H2NNMe2 (●), Dp44mT (─), 
DpC (●), Me2NNMe2 (×) and PTSC (▲). C: Correlation of pCu to the % of non-reduced 
copper(II) complexes calculated from GSH reduction studies. D: Correlations of the 
logarithmic reduction half-life of the TSC complexes by GSH to the anticancer activity (pIC50 
values) of metal-free ligands or copper(II) complexes in SW480 cells. R2 and p values have 
been calculated using Graph Pad prism software. E: Grouping of the compounds by vesicle 
induction (threshold: 10%) at 1 µM treatment metal-free ligand for 48 h in SW480 cells 
showed a slower copper(II) complex reduction by GSH in vesicle-inducing TSCs. 
Significance between groups was calculated by two-tailed T-test using GraphPad Prism 
software (** p < 0.01). Open symbols indicate nanomolar-active TSCs. F: Fold increase of 
superoxide levels by 5 µM treatment of indicated TSC copper(II) complexes in the presence 
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of 2 mM NAC was evaluated by the cell-free NBT assay. Values given are mean ± standard 
deviation of duplicates of two independent experiments. G: Correlation of pCu (indicating 
copper(II) complex stability) with superoxide production. Open symbols indicate 
nanomolar-active TSCs. R2 and p values have been calculated using Graph Pad prism 
software. 
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Figure 4: Upregulated redox stress signaling after TSC treatment. A: Intracellular 
superoxide production measured by flow cytometry of DHE fluorescence of MES-SA cells 
treated with 5 µM of indicated TSC with or without 2 mM NAC for 1 h. Values given are 
mean ± standard deviation of at least three independent experiments. B: Normalized 
mRNA expression values for SOD1/2/3 of SW480 cells untreated or treated with 0.1 µM 
Me2NNMe2, 1 µM Me2NNMe2 or 1 µM Triapine for 15 h were assessed by whole genome 
gene expression analysis performed with two technical replicates from two biological 
replicates. Normalization and annotation was performed with GeneSpring software 
(Agilent). C: Western blot analysis of SOD2 expressed by SW480 cells treated with 1 µM of 
the indicated TSC for 24 h. GAPDH was used as a loading control. Densitometric 
D
ow
nl
oa
de
d 
by
 N
or
th
w
es
te
rn
 U
ni
ve
rs
ity
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 0
5/
03
/2
0.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
Page 48 of 67 
 
 
 
48 
A
n
ti
o
xi
d
an
ts
 a
n
d
 R
e
d
o
x 
Si
gn
al
in
g
 
H
ig
h
 c
o
p
p
er
 c
o
m
p
le
x 
st
ab
ili
ty
 a
n
d
 s
lo
w
 r
e
d
u
ct
io
n
 k
in
et
ic
s 
as
 k
e
y 
p
ar
am
e
te
rs
 f
o
r 
im
p
ro
ve
d
 a
ct
iv
it
y,
 p
ar
ap
to
si
s 
in
d
u
ct
io
n
 a
n
d
 im
p
ac
t 
o
n
 d
ru
g
-r
e
si
st
an
t 
ce
lls
 o
f 
an
ti
ca
n
ce
r 
th
io
se
m
ic
ar
b
az
o
n
es
 (
D
O
I:
 
1
0
.1
0
8
9
/a
rs
.2
0
1
9
.7
8
5
4
) 
Th
is
 p
a
p
er
 h
as
 b
ee
n
 p
ee
r-
re
vi
ew
ed
 a
n
d
 a
cc
e
p
te
d
 f
o
r 
p
u
b
lic
at
io
n
, b
u
t 
h
as
 y
et
 t
o
 u
n
d
er
go
 c
o
p
ye
d
it
in
g
 a
n
d
 p
ro
o
f 
co
rr
ec
ti
o
n
. T
h
e 
fi
n
al
 p
u
b
lis
h
ed
 v
er
si
o
n
 m
ay
 d
if
fe
r 
fr
o
m
 t
h
is
 p
ro
o
f.
 
quantification using ImageJ of two separate experiments is given as mean ± standard 
deviation. Significance to control was calculated by one-way Anova and Dunnett’s multiple 
comparison test using GraphPad Prism software (** p < 0.01, * p < 0.05). D: Micromolar-
active TSC-treated SW480 cells express higher protein levels of SOD2 than nanomolar-
active TSC-treated cells. Open symbols indicate nanomolar active TSCs. E: Female Balb/c 
mice bearing subcutaneous CT-26 tumors were treated with solvent (10% DMSO, n = 4) or 
Triapine (10 mg/kg , n = 4) p.o. for 5 consecutive days a week for two weeks. Tumor were 
sampled and paraffin-embedded for immunohistochemical stain of SOD2. Representative 
images of the stain are depicted (scalebar = 50 µm). Percent highly positive SOD2-stained 
area of whole tissue slides were analysed by Definiens software. Significanct difference to 
solvent group was calculated by one-way ANOVA with Dunnett‘s multiple comparison test 
(* p < 0.05). F: GSEA from whole-genome gene expression data revealed significant 
enrichment in genes of the Gene Ontology term “Response to zinc ion” in SW480 cells 
treated with 1 µM Me2NNMe2 compared to untreated cells. Normalized enrichment score 
(NES) and false discovery rate (FDR) are given. G: Upregulation of metallothioneins and 
copper transporter ATP7A/B mainly contributed to the enrichment of the Gene Ontology 
term “Response to zinc ion” as seen by their individual mRNA expression levels given as 
mean log fold change to control ± standard deviation.  
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Figure 5: Inhibition of PDI by TSC copper(II) complexes. A: PDI activity was measured with 
10 or 100 µM of indicated TSC copper(II) complexes or copper alone using the 
PROTEOSTAT PDI assay kit. B: TSC complexes that inhibit PDI above levels of copper ions 
alone also showed higher pCu (indicating copper(II) complex stability), anticancer activity 
(in SW480 cells) and vesicle formation (in SW480 cells). Open symbols indicate nanomolar-
active TSCs. C: Correlation matrix of measured chemical and biological parameters in MES-
SA cells. P-values corrected for multiple comparisons (q-value) with an FDR of 1% are 
indicated with grayscale and were calculated with GraphPad Prism 8. Labels on x-axis are 
grouped thematically on the y-axis for a better overview. D: Differences in the proposed 
mode of action of nanomolar-active TSCs (represented by Me2NNMe2) and micromolar-
active TSCs (represented by Triapine).  
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